Stephane Bancel, the CEO of Moderna, defended the company against criticism of its pricing plans for the Covid-19 vaccine, The Wall Street Journal’s Jared S. Hopkins reports. At Monday’s Wall Street Journal Health Forum, Bancel said the company’s mRNA platform was funded by investors, not the government, and the public funding accelerated development of the vaccine. The CEO of Moderna, which has been questioned about its strategy around commercial pricing, said "We didn’t get a penny," and that the company unsuccessfully sought funding in the first half of 2020 from countries and foundations to help with manufacturing. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRNA:
- Moderna initiated with an Outperform at RBC Capital
- Moderna, Pfizer: Top mRNA Innovator Stocks are Oversold
- Moderna price target lowered to $200 from $225 at Deutsche Bank
- SVB downgrades Moderna to Underperform as COVID boom reverses
- Moderna downgraded to Underperform from Market Perform at SVB Securities